Completed PHASE3 INTERVENTIONAL 2-arm NCT02521168

Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia (OTICC)

Sponsor: CRDF Global

Conditions Postoperative; Dysfunction Following Cardiac Surgery

Interventions Oral triiodothyronine Placebo

Updated 5 times since 2017 Last updated: Feb 16, 2016 Started: Jul 31, 2013 Primary completion: Oct 31, 2014 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Postoperative; Dysfunction Following Cardiac Surgery, this trial is completed. The trial is conducted by CRDF Global and has accumulated 5 data snapshots since 2013. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CRDF Global
Dalim BioTech Co., Ltd.
National Cardiovascular Center Harapan Kita Hospital Indonesia
Osypka Germany

Data source: National Cardiovascular Center Harapan Kita Hospital Indonesia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jakarta, Indonesia